Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CerusSTU:CU2 +0.86%78 Debt-to-Equity is 1.10 as of Jun. 2026, which is 5% above its 10-year median of 1.05. GuruFocus rates STU:CU2 with a GF Score™ of 78/100 and a GF Value™ of €1.97 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 697 Medical Devices & Instruments companies, Cerus ranks worse than 87.66% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Cerus's Debt-to-Equity or its related term are showing as below:
STU:CU2'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27 Med: 1.05 Max: 2.04
Current: 1.1
During the past 13 years, the highest Debt-to-Equity Ratio of Cerus was 2.04. The lowest was 0.27. And the median was 1.05.
STU:CU2's Debt-to-Equity is ranked worse than 87.66% of 697
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs STU:CU2: 1.10
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Cerus Debt-to-Equity Related Terms
Cerus Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Cerus's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CU2 vs CTKB, TCMD, CBLL: Debt-to-Equity Comparison
For the Medical Devices subindustry, Cerus's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Cerus's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (STU:CU2) has a Debt-to-Equity of 1.10 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cerus and its competitors. This is near median its historical median of 1.05. Over the past decade, Cerus' Debt-to-Equity has ranged from 0.27 to 2.04. According to the industry distribution chart, Cerus ranks #611 out of 697 companies in the Medical Devices & Instruments industry, placing it in the top 87.7%.
Is Cerus' Debt-to-Equity too high?
Cerus' current Debt-to-Equity of 1.10 is near median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 2.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Cerus' value of 1.10 is 358.3% above this industry median. Based on the distribution chart, Cerus ranks #611 out of 697 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cerus has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cerus' Debt-to-Equity compare to CTKB and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cerus ranks #611 out of 697 companies for Debt-to-Equity. This places Cerus in the lower half of its industry. The industry median Debt-to-Equity is 0.24. Cerus' value of 1.10 is 358.3% above this benchmark. Historically, Cerus' own Debt-to-Equity has ranged from 0.27 to 2.04 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 0.24, Cerus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 697 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cerus's current Debt-to-Equity of 1.10 is 358.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cerus and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cerus's current Debt-to-Equity is 1.10, which is near median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (STU:CU2) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.97, compared to a current price of €2.34 — trading 18.8% above its estimated fair value. The current Debt-to-Equity is 1.10, which is near median its 10-year median of 1.05 and 358.3% above the Medical Devices & Instruments industry median of 0.24. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Cerus (STU:CU2), the current Debt-to-Equity is 1.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cerus (STU:CU2) Overvalued in 2026?
Based on GuruFocus' analysis, Cerus stock appears to be overvalued.
The current stock price of €2.34 is trading 18.8% above its estimated GF Value™ of €1.97.
GuruFocus considers Cerus to be Modestly Overvalued.
Key valuation signals for STU:CU2:
Debt-to-Equity: 1.10 (near median its 10-year median of 1.05)
GF Value™: €1.97 vs. price of €2.34 (18.8% above fair value)
Industry Position: 358.3% above the Medical Devices & Instruments median (#611 of 697)
No single metric tells the full story. See the STU:CU2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score
Get the complete analysis for STU:CU2
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CU2 has been successfully added to your 
